Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08046050 · 1 trial · 6 indications
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
| Arm | Type | Description |
|---|---|---|
| PF-08046050 | EXPERIMENTAL | PF-08046050 monotherapy |
| PF-08046050 +bevacizumab | EXPERIMENTAL | PF-08046050 combination with bevacizumab |
| PF-08046050 + bevacizumab + 5FU/LV | EXPERIMENTAL | PF-08046050 combination with bevacizumab + 5FU/LV |
| PF-08046050 + 5FU/LV + oxaliplatin + bevacizumab | EXPERIMENTAL | PF-08046050 combination with 5FU/LV + oxaliplatin + bevacizumab |
| PF-08046050 + 5FU/LV + oxaliplatin | EXPERIMENTAL | PF-08046050 combination with 5FU/LV + oxaliplatin |
| PF-08046050 + 5FU/LV | EXPERIMENTAL | PF-08046050 combination with 5FU/LV |
| Name | Type | Description |
|---|---|---|
| PF-08046050 | DRUG | Given into the vein (IV; intravenous) |
| bevacizumab | DRUG | Given into the vein (IV; intravenous) |
| 5-Fluorouracil (5-FU) | DRUG | Given into the vein (IV; intravenous) |
| Oxaliplatin | DRUG | Given into the vein (IV; intravenous) |
| Leucovorin (LV) | DRUG | Given into the vein (IV; intravenous) |
Inclusion Criteria: 1. Tumor type: * Participants in Part A (dose escalation) and Part B (dose optimization) must have histologically- or cytologically-confirmed metastatic or unresectable solid tumor malignancy. Must have relapsed, refractory, or progressive disease, and should have no appropr...
PF-08046050 is an investigational small molecule being developed for the treatment of colorectal neoplasms. It is also being studied in other advanced solid tumors, including non-small-cell lung cancer, stomach cancer, pancreatic ductal adenocarcinoma, gastroesophageal junction adenocarcinoma, and small cell lung carcinoma.
PF-08046050 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
PF-08046050 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is currently being evaluated in an active, recruiting Phase 1 clinical trial.
PF-08046050 is being studied in one active Phase 1 clinical trial, identified as NCT06131840. This trial is titled "A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors" and is currently recruiting participants.
Yes, PF-08046050 is also known as SGN-CEACAM5C. The ongoing Phase 1 clinical trial NCT06131840 uses the name SGN-CEACAM5C in its title, indicating that these names refer to the same investigational drug.